S1PR1 and multiple sclerosis: In Zhang et al.8, usage of the S1P analog FTY720 (Fingolimod, which is now approved for therapy in multiple sclerosis), led to decline in membrane S1PR1 levels (through prolonged receptor activation and subsequent internalization) and subsequently protecting cardiac function, in contrast to the findings mentioned above.